Gene therapy: miracle for a few or cure for many?
Event details
- Date
- Wednesday, 23 October - 18:00
- Place
- Novartis Pavillon
- Genre
- Conferences
- Organiser
- INSEAD Alumni Association Switzerland
Description
Gene therapy: miracle for a few or cure for many?Panel discussion and Q&A Wednesda, 23 October 2024Since the approval in 2003 in China of the first commercial gene therapy, Gendicine, gene therapy has emerged as a miracle modality for many previously hard-to-treat diseases. Examples include Novartis’ Zolgensma for spinal muscular atrophy (SMA), CSL Behring’s Hemgenix for hemophilia B, and Janssen’s Carvykti for multiple myeloma. In this panel discussion, five industry experts will address a broad range of questions, including: In the past, what were the limitations of gene therapy, particularly in Europe? What costs are expected to be classified by payers as reimbursable, and for which indications? Is cost of manufacturing the key limitation making these therapies cheaper and, if yes, can costs be reduced by 90% or more per treatment? Will gene therapy expand to more indications and benefit more people? What could a successful gene therapy business model look like in the future?The discussion will be followed by networking drinks during which you can continue the discussion with the panelists and fellow alumni. Programme 17:30 Self-tour of exhibition “Wonders of Medicine”18:00 Door opening18:30 Panel discussion19:30 Networking Drinks21:00 Closing Key FactsWhen: Wednesday, 23 October 2024, 18:00Where: Novartis Pavillon, St. Johanns-Hafen-Weg 5, 4056 Basel (public transportation recommended, limited parking available at Novartis Campus, Fabrikstrasse 2)Tickets: CHF 70 NAA Members (paid-up) and CHF 95 Alumni non-members and guests Ticketing closes 24h before the event. INSEAD Alumni Association SwitzerlandEvent organizers:Eric de La Fortelle, MBA’99DVictor Zambrano, MBA’08DAleks Ruzicic, MBA’97J events@insead.ch